Gene Virus

基因和病毒治疗计划(GVTP)目前有12名成员，包括基础科学家和 来自八个科室的临床医生研究人员互动工作，开发新的， 基于基因的癌症治疗方法。该计划的目标是：(1)加强 了解用于创造新基因传递系统的病毒和细胞的生物学；(2) 发展新的基因及病毒疗法的技术基础；及。(三) 通过开发新的基于基因和病毒的疗法和测试来改善癌症治疗的结果 他们在诊所里。主要研究主题是(I)临床前和临床药理学；(Ii)媒介 靶向；(Iii)蜂窝载体；以及(Iv)免疫调节。程序内部交互是密集的， 包括多项合作、定期的操作教员会议和 定期期刊俱乐部和方案研讨会的背景。方案间实质性互动， 在临床翻译过程中必不可少的，已经在基因和病毒治疗之间建立 计划，免疫学和免疫治疗计划，血液恶性疾病计划， 妇女癌症计划、胃肠道癌症计划和神经肿瘤学计划。这个 基因和病毒治疗计划得益于斯蒂芬·拉塞尔的强大领导，医学博士，博士， 在基因和病毒治疗领域颇具声望的血液学家。美国国立卫生研究院为此提供的资金基础 目前，该计划每年的总费用为350万美元，其中58%来自国家癌症 研究所。在本供资期间，该方案的生产力一直很高，达到 共有320篇文献和4项I期临床试验，其中设计了重组病毒， 由梅奥诊所罗切斯特制造、临床前测试和制造的药物适用于患有 各种类型的癌症。此外，还有几个非常有希望的项目正在翻译中， 包括设在罗切斯特的GVTP与 亚利桑那州梅奥诊所的胃肠道癌症计划推进重组溶瘤囊泡 口腔炎病毒在肝细胞癌患者中的临床检测。 共320份出版物；17%为方案内出版物；23%为方案间出版物

The Gene & Virus Therapy Program (GVTP) currently comprises twelve members, both basic scientists and clinician investigators from eight departments and divisions working interactively to develop novel, genetically based approaches to the treatment of cancer. The goals of the program are: (1) to enhance understanding of the biology of the viruses and cells that are used to create new gene delivery systems; (2) to advance the technology base from which new gene and virus based therapies can be created; and (3) to improve the outcomes of cancer treatment by developing new gene and virus based therapies and testing them in the clinic. The major research themes are (I) preclinical and clinical pharmacology; (II) vector targeting; (III) cellular carriers; and (IV) imrhunomodulation. Intra-programmatic interactions are intensive, comprising multiple collaborations, regular operational faculty meetings, and scientific exchanges in the context of regular journal clubs and programmatic seminars. Substantive inter-programmatic interactions, essential for the process of clinical translation, have been established between the Gene & Virus Therapy Program, the Immunology & Immunotherapy Program, the Hematologic Malignancies Program, the Women's Cancer Program, the Gastrointestinal Cancer Program, and the Neuro-oncology Program. The Gene & Virus Therapy Program benefits from the strong leadership of Stephen Russell, MD, PhD, a hematologist with considerable stature in the field of gene and virus therapy. The NIH funding base for this program currently stands at $3.5 million per annum in total costs of which 58% is from the National Cancer Institute. Productivity of the program during the current funding period has been substantial, amounting to a total of 320 publications and four Phase I clinical trials in which recombinant viruses that were designed, built, preclinically tested, and manufactured at Mayo Clinic Rochester are being administered to patients with various types of cancer. Additionally, there are several very promising projects in the translational pipeline, including a major inter-programmatic collaboration between the GVTP in Rochester and members of the Gastrointestinal Cancer Program in Mayo Clinic Arizona to advance a recombinant oncolytic vesicular stomatitis virus to clinical testing in patients with hepatocellular carcinoma. 320 total publications; 17% intra-programmatic; 23% inter-programmatic